Evidence map›Paper›PMID 30419926›Full record

ArticleHarm reduction journal2018

Perspectives on HIV pre-exposure prophylaxis (PrEP) utilization and related intervention needs among people who inject drugs.

K B Biello, A R Bazzi, M J Mimiaga, D L Biancarelli, A Edeza, P Salhaney, E Childs, M L Drainoni

2 registry-linked trialsOpen access · goldAbstract readMulticenter Study
In one paragraph

Article in Harm reduction journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 112 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
112citing papers in PubMed, 5 pooled it
6.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06025435 naactive not recruitingnot on this mapstarted 2023, after this paper: background citation

SAIA-SSP-HIV: a Systems Analysis and Improvement Approach to Optimizing HIV Service Delivery in Syringe Services Programs

TypeinterventionalSponsorUniversity of California, San DiegoRan2023 to 2027Enrolled32ConditionsHIV InfectionsArmsSAIA-HIV-SSP
NCT07385183 not yet recruitingnot on this mapstarted 2026, after this paper: background citation

CARE: Comprehensive Assessment of Real-world Effectiveness of F/TAF in Persons Who Use Drugs (PWUD)

TypeobservationalSponsorHeather HendersonRan2026 to 2027Enrolled200ConditionsPeople Who Inject Drugs, PrEP AdherenceArmsPrEP adherence, PrEP perspectives
3 · Its place in the literature

Who cites it

112 citing papers in PubMed, 5 syntheses or guidelines pooled it, 133 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

52 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

K B BielloDepartments of Behavioral and Social Sciences and Epidemiology, Center for Health Equity Research, Brown University School of Public Health, Box G-S121-8, Providence, RI, 02912, USA. katie_biello@brown.edu.
A R BazziDepartment of Community Health Sciences, Boston University School of Public Health, Boston, MA, USA.
M J MimiagaDepartments of Behavioral and Social Sciences and Epidemiology, Center for Health Equity Research, Brown University School of Public Health, Box G-S121-8, Providence, RI, 02912, USA.
D L BiancarelliDepartment of Health Law, Policy & Management, Boston University School of Public Health, Boston, MA, USA.
A EdezaCenter for Health Equity Research, Brown University, Providence, RI, USA.
P SalhaneyCenter for Health Equity Research, Brown University, Providence, RI, USA.
E ChildsDepartment of Health Law, Policy & Management, Boston University School of Public Health, Boston, MA, USA.
M L DrainoniDepartment of Health Law, Policy & Management, Boston University School of Public Health, Boston, MA, USA.
Boston University · USBrown University · USFenway Health · US

Funding

Translational ScienceP30AI042853 · NIAID · MIRIAM HOSPITAL · PI CURT G BECKWITH · 1998 to 2026
$51.7M
Preventing HIV infection among people who inject drugs during COVID-19K01DA043412 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BAZZI, ANGELA ROBERTSON · 2017 to 2021
$934k
NIAID NIH HHS P30 AI042853NIDA NIH HHS K01 DA043412NIDA NIH HHS K01DA043412Providence/Boston Center for AIDS Research P30AI042853
6 · The paper itself

Abstract

backgroundAntiretroviral pre-exposure prophylaxis (PrEP) is clinically efficacious and recommended for HIV prevention among people who inject drugs (PWID), but uptake remains low and intervention needs are understudied. To inform the development of PrEP interventions for PWID, we conducted a qualitative study in the Northeastern USA, a region where recent clusters of new HIV infections have been attributed to injection drug use.

methodsWe conducted qualitative interviews with 33 HIV-uninfected PWID (hereafter, "participants") and 12 clinical and social service providers (professional "key informants") in Boston, MA, and Providence, RI, in 2017. Trained interviewers used semi-structured interviews to explore PrEP acceptability and perceived barriers to use. Thematic analysis of coded data identified multilevel barriers to PrEP use among PWID and related intervention strategies.

resultsAmong PWID participants (n = 33, 55% male), interest in PrEP was high, but both participants and professional key informants (n = 12) described barriers to PrEP utilization that occurred at one or more socioecological levels. Individual-level barriers included low PrEP knowledge and limited HIV risk perception, concerns about PrEP side effects, and competing health priorities and needs due to drug use and dependence. Interpersonal-level barriers included negative experiences with healthcare providers and HIV-related stigma within social networks. Clinical barriers included poor infrastructure and capacity for PrEP delivery to PWID, and structural barriers related to homelessness, criminal justice system involvement, and lack of money or identification to get prescriptions. Participants and key informants provided some suggestions for strategies to address these multilevel barriers and better facilitate PrEP delivery to PWID.

conclusionsIn addition to some of the facilitators of PrEP use identified by participants and key informants, we drew on our key findings and behavioral change theory to propose additional intervention targets. In particular, to help address the multilevel barriers to PrEP uptake and adherence, we discuss ways that interventions could target information, self-regulation and self-efficacy, social support, and environmental change. PrEP is clinically efficacious and has been recommended for PWID; thus, development and testing of strategies to improve PrEP delivery to this high-risk and socially marginalized population are needed.

Indexed as

AdultAgedAnti-HIV AgentsFemaleHIV InfectionsHumansIllicit DrugsMaleMiddle AgedNeeds AssessmentPre-Exposure ProphylaxisProcedures and Techniques UtilizationSubstance Abuse, IntravenousYoung AdultAnti-HIV AgentsIllicit DrugsHIV preventionIntervention developmentPre-exposure prophylaxisPWID

Identifiers

PMID30419926
PMCPMC6233595
OpenAlexW2900955172

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.